A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD.

J Atten Disord · 2020 · PMC6939319 · PMID 30924702

Europe PMC DOI

hedged sentence

0.1010

closest p · 2.0× alpha

0.1010

boldest claim

The sentences

did not reach statistical significancep = .101not close (p > 0.1)

The LS mean change from Baseline to EOS did not reach statistical significance between placebo and SPN-812 dose group (100 mg, p = .101; 200 mg, p = .091; 300 mg, p = .055; 400 mg, p = .053); however, there was a trend for the scores to be lower in the 300 and 400 mg SPN-812 dose groups.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.